Tumors with activated EGF receptors can be treated with drugs that inhibit the kinase activity by binding to intracellular domains. Most of these drugs are ATP analogs that block ATP binding and thus prevent auto- and transphosphorylation by the intracellular receptor domains. Mutations in signaling proteins downstream of the EGF receptors may lead to resistance to these EGF receptor tyrosine kinase inhibitors.

Check related videos:

The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors – Part 1: Inhibition of receptor activation via antibodies

The EGF receptor tyrosine protein kinases